Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 20, Issue 4, Pages 593-596Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543771003662636
Keywords
DITPA; metabolic syndrome; thyroid hormone receptor; thyromimetics
Categories
Ask authors/readers for more resources
The patent application WO2008106213 describes the beneficial effects of thyroid hormone analogue 3,5 diiodothyropropionic acid (DITPA) such as stimulating weight loss in overweight mammals, lowering of triglyceride and treating metabolic syndrome in humans. The human population of the patients selected in the studies mentioned has a body mass index > 25. Two examples of the human clinical studies employing DITPA have been mentioned, namely, the body weight reduction and improvement in metabolic abnormalities in obese adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
